1. Financial Highlights: Consolidated total income declined 8.7% to Rs 306.15 Cr from Rs 335.39 Cr year-on-year, due to absence of past non-recurring projects.

Profit before tax fell 53.8% to Rs 24.77 Cr.

EBITDA margin compressed sharply to 13.5% from 22.2%, reflecting increased spend on new capabilities and R&D. PAT dropped 50% to Rs 18.66 Cr with margin at 6.1%, impacted by capacity additions, leadership hires, AI initiatives, and syndicated research development costs.

2. Strategic Initiatives & Growth Drivers: Expanded capacity with a 600-seat Customer Experience Centre and 346-seat Computer Aided Telephonic Interview platform.

Major investments underway in AI-based product development and syndicated research offerings.

Launched the R K SWAMY Centre for Study of Indian Markets and enhanced video production capabilities for large-format anamorphic displays.

Continued focus on scaling pharmaceutical sector services.

3. Business Developments: Promoters boosted stake from 66.05% to 69.61%, acquiring a 3.56% US-based investor holding and waived their 1% net profit commission, signaling strong long-term confidence.

Hansa Research secured ISO certification, reinforcing research quality credentials.

4. Market Position & Competitive Advantage: The group delivers integrated marketing solutions across creative, media, analytics, and research via multiple brands.

AI integration and expanded capacity position it well to meet evolving data-driven client demands.

Their single-window model supports seamless end-to-end client engagement and service.

5. Investor Implications: Margin pressure and profit decline reflect strategic investment phases, but capacity buildout and technology upgrades underpin positive growth potential.

Promoter confidence is a strong endorsement, though execution risks remain as initiatives scale.

Long-term outlook appears constructive for value creation.